Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph II trial of osimertinib w/ or w/o bevacizumab in pts w/ EGFR mutation pos NSCLC & brain metastase

Protocol: OSU-18071

Full Title

A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases

Lung Cancers